Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Intensive Care Medicine

• Publication date

  2016-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00134-015-4188-0PMID 26754759
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

  2016cited by this paper
• Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.

  2015cited by this paper
• A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.

  2015cited by this paper
• Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

  2015cited by this paper
• Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.

  2015cited by this paper
• The BLISS study: Beta-Lactam infusion in severe sepsis-randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis in a Malaysian ICU setting

  2015cited by this paper
• Comparison of different equations to assess glomerular filtration in critically ill patients

  2015cited by this paper
• Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients

  2014cited by this paper
• DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

  2014cited by this paper
• A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).

  2014cited by this paper
• Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

  2014cited by this paper
• Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock

  2013cited by this paper
• Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?

  2013cited by this paper
• Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.

  2013cited by this paper
• Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012

  2013cited by this paper
• Standard Versus Prolonged Doripenem Infusion for Treatment of Gram-Negative Infections

  2013cited by this paper
• Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections

  2013cited by this paper
• Protein Binding of Beta-Lactam Antibiotics in Critically Ill Patients: Can we successfully

  2013cited by this paper
• Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.

  2013cited by this paper
• Continuous beta-lactam infusion in critically ill patients: the clinical evidence

  2012cited by this paper
• Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

  2012cited by this paper
• Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.

  2012cited by this paper
• Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection.

  2010cited by this paper
• A systematic review on clinical benefits of continuous administration of &bgr;-lactam antibiotics*

  2009cited by this paper
• Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

  2008cited by this paper
• Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.

  2007cited by this paper
• Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection

  2006cited by this paper
• Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.

  2006influential reference
• Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.

  2006cited by this paper
• Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.

  2005cited by this paper
• Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials.

  2005cited by this paper
• Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis.

  2003cited by this paper
• Serial evaluation of the SOFA score to predict outcome in critically ill patients.

  2001cited by this paper
• Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.

  2001cited by this paper
• Intermittent and continuous ceftazidime infusion for critically ill trauma patients.

  2000influential reference
• Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

  2000cited by this paper
• Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

  1998cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper
• APACHE II: A severity of disease classification system

  1985cited by this paper
• A method for estimating the probability of adverse drug reactions

  1981cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Prolonged infusion of β-lactam antibiotics decreases short-term mortality in critically ill patients: a meta-analysis and trial sequential analysis from randomized control trials.

  2025cites this paper
• Optimizing Antibiotic Choice, Administration, and Duration in NSTI Treatment

  2025cites this paper
• Antibiotic therapy for severe bacterial infections

  2025cites this paper
• Continuous vs. intermittent meropenem infusion in critically ill patients with sepsis: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis

  2025cites this paper
• Antibacterial Pharmacokinetics in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO): A Systematic Review of Population Pharmacokinetic Studies

  2025influential citation
• Prolonged vs. Short-Term Infusion of Imipenem/Cilastatin for Multidrug-Resistant Gram-Negative Bacilli Severe Pneumonia: A Randomized Controlled Trial Evaluating Efficacy, Safety, and Cost-Effectiveness

  2025cites this paper
• Enhancing Meropenem Therapy in Critical Care: A Retrospective Study of PK/PD Target Attainment and Therapeutic Drug Monitoring.

  2025cites this paper
• Exposure levels and target attainment of meropenem in adult patients admitted to the intensive care unit: a prospective observational study.

  2025cites this paper
• Continuous or extended vs intermittent infusions of beta-lactam antibiotics in ICU patients with pneumonia: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: a randomized controlled trial.

  2025cites this paper
• Impact of prolonged versus intermittent infusion of meropenem on mortality and clinical outcomes in patients with severe infection: A systematic review and meta-analysis.

  2025cites this paper
• The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024

  2025cites this paper
• The Impact of Beta-Lactam Antibiotic Timing on Patient Outcomes in Post-Operative Sepsis Management: A Multi-Center Analysis of Orthopedic and General Surgery Cases

  2025cites this paper
• The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024

  2025cites this paper
• Prolonged versus short-term infusion of meropenem for the treatment of sepsis: a systematic review and meta-analysis

  2025cites this paper
• Continuous versus intermittent infusion of β-lactams in patients with sepsis and septic shock: a systematic review and meta-analysis

  2025influential citation
• Meropenem dosing optimization on day 1 and steady state in critically ill patients without significant renal impairment

  2025cites this paper
• ElastoMeric Infusion Pumps for Hospital AntibioTICs (EMPHATIC): A Feasibility Study

  2025cites this paper
• Continuous infusion of Beta-Lactams in the critically ill: Considerations for global implementation.

  2025cites this paper
• Prolonged versus intermittent β-lactam infusion in sepsis: a systematic review and meta-analysis of randomized controlled trials

  2024influential citation
• Carrimycin ameliorates lipopolysaccharide and cecal ligation and puncture-induced sepsis in mice.

  2024cites this paper
• Detailed regimens for the prolonged β-lactam infusion therapy.

  2024cites this paper
• Improving cefazolin exposure in critically ill children using a population pharmacokinetic model

  2024cites this paper
• Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing

  2024cites this paper
• Meta-analysis on safety of standard vs prolonged infusion of beta-lactams.

  2024cites this paper
• Guidelines for Antibiotics Prescription in Critically Ill Patients

  2024cites this paper
• Extended-Infusion β-Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram-Negative Bloodstream Infections

  2024cites this paper
• Meropenem pharmacokinetics in cerebrospinal fluid: comparing intermittent and continuous infusion strategies in critically ill patients—a prospective cohort study

  2024cites this paper
• A Retrospective Analysis of Intravenous Push versus Extended Infusion Meropenem in Critically Ill Patients

  2024cites this paper
• At the Intersection of Critical Care and Infectious Diseases: The Year in Review

  2024cites this paper
• Improving pharmacokinetic/pharmacodynamic outcomes of antimicrobial therapy for pneumonia in the ICU

  2024cites this paper
• Extended Infusion of Beta-Lactams and Glycopeptides: A New Era in Pediatric Care? A Systematic Review and Meta-Analysis

  2024cites this paper
• Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis.

  2024cites this paper
• Decreased risk of underdosing with continuous infusion versus intermittent administration of cefotaxime in patients with sickle cell disease and acute chest syndrome

  2024cites this paper
• Continuous versus intermittent infusion of beta-lactam antibiotics: where do we stand today? A narrative review.

  2024cites this paper
• Revealing the role of Peg13: A promising therapeutic target for mitigating inflammation in sepsis

  2024cites this paper
• Management of Ventilator-Associated Pneumonia: Guidelines.

  2024cites this paper
• Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review

  2023cites this paper
• Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs

  2023influential citation
• Efficacy of drug treatment for severe melioidosis and eradication treatment of melioidosis: A systematic review and network meta-analysis

  2023influential citation
• Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.

  2023influential citation
• Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections

  2023cites this paper
• Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?

  2023cites this paper
• Optimizing Betalactam Clinical Response by Using a Continuous Infusion: A Comprehensive Review

  2023cites this paper
• Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia

  2023cites this paper
• Clinical efficacy and safety of prolonged versus intermittent administration of antipseudomonal beta-lactam antibiotics in adults with severe acute infections: A meta-analysis of randomized controlled trials.

  2023cites this paper
• Advances in antibacterial treatment of adults with high-risk febrile neutropenia.

  2023cites this paper
• Continuous infusion of beta-lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy

  2023cites this paper
• The Influence of Extracorporeal Membrane Oxygenation on Antibiotic Pharmacokinetics

  2023cites this paper
• Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling

  2023cites this paper
• Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance

  2023cites this paper
• A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime‐avibactam in a case series of critically ill patients with augmented renal clearance

  2023cites this paper
• Interprofessional Therapeutic Drug Monitoring of Carbapenems Improves ICU Care and Guideline Adherence in Acute-on-Chronic Liver Failure

  2023cites this paper
• Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients

  2023cites this paper
• Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy

  2023cites this paper
• Fokus Sepsis und allgemeine Intensivmedizin 2022/2023

  2023cites this paper
• Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies

  2023cites this paper
• Antiinfektive Therapie in der Intensivmedizin

  2023cites this paper
• Prolonged vs intermittent intravenous infusion of β-lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis

  2023influential citation
• Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study.

  2023cites this paper
• A multifaceted strategy to optimize pharmacokinetics of antimicrobial therapy in patients with hospital-acquired infections-a monocentre quality improvement project.

  2023cites this paper
• Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect Modeling

  2023cites this paper
• Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients—A Narrative Review

  2023cites this paper
• Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients

  2023cites this paper
• Pharmacokinetic-Pharmacodynamic and Clinical Considerations for Extended- and Continuous-Infusion Antibiotics

  2023cites this paper
• Mortality of continuous infusion versus intermittent bolus of meropenem: a systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients

  2022cites this paper
• A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.

  2022cites this paper
• Optimizing antibiotic therapies to reduce the risk of bacterial resistance.

  2022cites this paper
• Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study

  2022cites this paper
• Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective

  2022cites this paper
• Major Publications in the Critical Care Pharmacotherapy Literature: 2021

  2022cites this paper
• In silico evaluation of a beta‐lactam dosing guideline among adults with serious infections

  2022cites this paper
• Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity

  2022cites this paper
• Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study

  2022cites this paper
• Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment

  2022cites this paper
• Factors associated with the decision to administer β-lactams via prolonged infusion in patients with sepsis: a prospective observational cohort study.

  2022cites this paper
• Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients.

  2022cites this paper
• Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis

  2022cites this paper
• Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’

  2022cites this paper
• The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial.

  2022cites this paper
• Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings

  2022cites this paper
• Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.

  2022cites this paper
• β-lactam precision dosing in critically ill children: Current state and knowledge gaps

  2022cites this paper
• Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis

  2022cites this paper
• Research priorities towards precision antibiotic therapy to improve patient care.

  2022cites this paper
• Issues in antibiotic therapy for hospital-acquired and ventilator-associated pneumonia: emerging concepts to improve outcomes

  2021cites this paper
• Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy

  2021cites this paper
• Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae

  2021cites this paper
• Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy

  2021cites this paper
• Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors

  2021cites this paper
• The case for precision dosing: medical conservatism does not justify inaction.

  2021cites this paper
• Advancing pediatric antimicrobial stewardship: Has pharmacodynamic dosing for gram-negative infections taken effect?

  2021cites this paper
• A narrative review on antimicrobial therapy in septic shock: updates and controversies.

  2021cites this paper
• Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion

  2021cites this paper
• Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses

  2021influential citation
• Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments

  2021cites this paper
• Personalized Antibiotic Therapy for the Critically Ill: Implementation Strategies and Effects on Clinical Outcome of Piperacillin Therapeutic Drug Monitoring—A Descriptive Retrospective Analysis

  2021cites this paper
• Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study.

  2021cites this paper
• Antibiotics in Necrotizing Soft Tissue Infections

  2021cites this paper